Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Every person has the right to expect that when they use a medical product, whether medicine, vaccine or diagnostic kit, it works. But too often, that is not the case. Substandard medical products result from errors, negligence or poor practice in manufacturing, transportation and/or storage. In contrast, falsified products result from criminal fraud. Both innovative and generic products are affected.

Poster: Let's demand medicines we can trust. The Oxford Statement. Medicine quality & public health.

“Access to safe and effective medical coverage is essential to WHO goals. There is no universal health coverage, no health security without access to quality medicines.”

Dr. Tedros Adhanom Ghebreyesus, Director General of WHO, 27 September 2018

While substandard and falsified (SF) medical products are found worldwide, they are more prevalent in countries with under-resourced national medicine regulatory authorities (NMRAs).

Representatives of governments, national and international agencies, non-governmental organisations, professional associations and academic institutions participated in the 1st International Conference on Medicine Quality & Public Health at Keble College, Oxford 23-28 September 2018.

The conference discussed the latest evidence on the epidemiology of SF medical products, their health, economic, social, legal and ethical implications, and debated interventions to ensure that all the world’s population have access to affordable and quality-assured medical products.

The organisations comprising the #MedsWeCanTrust Campaign and others listed below reached consensus that:

  • The quality of medical products is critical to protect lives globally. Substandard and falsified medical products negate the benefits of access to modern healthcare, especially for the most vulnerable.
  • We must work collaboratively across sectors to raise awareness, encourage political will, investment and action to make quality medical products affordable and accessible to all.
  • We will work in support of WHOs recommendation for the Prevent, Detect and Respond framework against SF medical products and for the global strengthening of medicines regulatory systems.
  •  We call on governments, national and international organisations and funders to prioritise human capacity and financial investment to ensure effective, efficient and consistent quality assurance by all NMRAs, including improved data sharing and harmonisation, with linked efficient procurement and supply systems leading to equitable access and improved global health.

A detailed consensus statement is in development with all conference partners comprising priorities and recommendations for the Medicine Quality community. It is anticipated this will be published in 2019.

The full story is available on the Medicines We Can Trust website

Similar stories

Study calls for rapid sharing of data to monitor artemisinin resistance

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.

Global Research on AntiMicrobial resistance (GRAM) project

Antimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year — with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.

Susie, Phaik Yeong, Richard and Paul among new full Oxford professors!

In the 2021 Oxford Recognition of Distinction round, four MORU colleagues were awarded Full Professor title.

RECOVERY Trial launches in South Africa

The world’s largest clinical trial investigating treatments for COVID-19 has now launched in South Africa, with the first patient recruited today. This is the fifth country to take part in RECOVERY, joining Nepal, Indonesia, Vietnam, and the United Kingdom.

RECOVERY Trial wins ‘Oscar of Higher Education’ for STEM Research Project of the year

The RECOVERY Trial has been awarded the 2021 Times Higher Education (THE) Award in the ‘Research Project of the Year: STEM’ category.

All-nighter: staying up to fight malaria

Featured in Nature, Victor Chaumeau collects mosquitoes in Myanmar to better understand how to control malaria.